Share-based Payment Arrangement, Expense of Zentalis Pharmaceuticals, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Zentalis Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Zentalis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,828,000, a 53% decline year-over-year.
  • Zentalis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $48,963,000, a 1.7% decline year-over-year.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $67,269,000, a 23% increase from 2023.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $54,822,000, a 17% increase from 2022.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $46,840,000, a 31% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Zentalis Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $48,963,000 $4,828,000 -$5,534,000 -53% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $54,497,000 $6,286,000 -$6,425,000 -51% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $60,922,000 $6,486,000 -$6,347,000 -49% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $67,269,000 $31,363,000 +$17,483,000 +126% 01 Oct 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
Q3 2024 $49,786,000 $10,362,000 -$3,505,000 -25% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $53,291,000 $12,711,000 -$631,000 -4.7% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $53,922,000 $12,833,000 -$900,000 -6.6% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $54,822,000 $13,880,000 +$4,268,000 +44% 01 Oct 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
Q3 2023 $50,554,000 $13,867,000 +$3,550,000 +34% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $47,004,000 $13,342,000 -$3,422,000 -20% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $50,426,000 $13,733,000 +$3,586,000 +35% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $46,840,000 $9,612,000 +$1,141,000 +13% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2025 2024 FY
Q3 2022 $45,699,000 $10,317,000 +$2,661,000 +35% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $43,038,000 $16,764,000 +$6,845,000 +69% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $36,193,000 $10,147,000 +$456,000 +4.7% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $35,737,000 $8,471,000 +$584,000 +7.4% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $35,153,000 $7,656,000 +$407,000 +5.6% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $34,746,000 $9,919,000 +$2,238,000 +29% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $32,508,000 $9,691,000 +$9,362,000 +2846% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $23,146,000 $7,887,000 +$7,675,000 +3620% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 $15,471,000 $7,249,000 +$7,094,000 +4577% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $8,377,000 $7,681,000 +$7,560,000 +6248% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $817,000 $329,000 +$200,000 +155% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $617,000 $212,000 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $155,000 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $121,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $129,000 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1

Zentalis Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $67,269,000 +$12,447,000 +23% 01 Jan 2024 31 Dec 2024 10-K 26 Mar 2025 2024 FY
2023 $54,822,000 +$7,982,000 +17% 01 Jan 2023 31 Dec 2023 10-K 26 Mar 2025 2024 FY
2022 $46,840,000 +$11,103,000 +31% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2025 2024 FY
2021 $35,737,000 +$12,591,000 +54% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $23,146,000 +$22,529,000 +3651% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $617,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.